Based on research from Karolinska Institutet, Gesynta is a pharmaceutical company that leverages expertise in arachidonic acid research to explore the use of mPGES-1 inhibition in cardiovascular diseases and cancer. The clinical candidate, GS-248, is an oral small molecule being developed for the treatment of microvascular disease in chronic inflammatory conditions. When strategically optimal, Gesynta will seek pharma partners to efficiently make the new therapies available to patients and to achieve the full commercial potential of its products. Gesynta is a privately held Swedish company located in Stockholm operating with a team of experts in the fields of mPGES-1 medical research, drug discovery and clinical and business development.
Gesynta Pharma at a glance
What they do: Developing novel oral treatments for patients with chronic inflammatory conditions
Founded in: 2017
Headquarters: Solna, Sweden